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A B S T R A C T
Next-generation sequencing has provided a more complete picture of the composition of the human tran-
scriptome indicating that much of the “blueprint” is a vastness of poorly understood non-protein-coding tran-
scripts. This includes a newly identified class of genes called long noncoding RNAs (lncRNAs). The lack of
sequence conservation for lncRNAs across species meant that their biological importance was initially met with
some skepticism. LncRNAs mediate their functions through interactions with proteins, RNA, DNA, or a combi-
nation of these. Their functions can often be dictated by their localization, sequence, and/or secondary structure.
Here we provide a review of the approaches typically adopted to study the complexity of these genes with an
emphasis on recent discoveries within the innate immune field. Finally, we discuss the challenges, as well as the
emergence of new technologies that will continue to move this field forward and provide greater insight into the
biological importance of this class of genes. This article is part of a Special Issue entitled: ncRNA in control of
gene expression edited by Kotb Abdelmohsen.
1. Introduction
One of the most profound discoveries from the sequencing of the
human genome is that over 85% of the genome is transcribed, yet< 2%
encodes protein-coding genes [1]. Large consortiums such as ENCODE
and FANTOM have embarked on attempting to characterize all func-
tional coding and noncoding elements in the genome and have com-
piled important regulatory data for these elements [2–4]. Long non-
coding RNAs (lncRNAs) represent the largest group of non-coding RNAs
produced from the genome. LncRNAs are defined as transcripts> 200
nucleotides in length, lacking protein-coding potential. In the most
recent GENCODE V30 release, there are 16,193 annotated lncRNAs in
the human genome [4]. Additionally, there are over 14,000 pseudo-
genes, that could fall under the description of long noncoding RNAs
which is simply based on them being 200 nucleotides or greater in
length. Less than ~3% of annotated lncRNAs have ascribed functions.
Hence this class of RNAs is greatly in need of further investigation [4].
From those that have been characterized, it is clear that lncRNAs can
function through a variety of mechanisms to regulate gene expression
both at the transcriptional and post-transcriptional levels [5].
As we will discuss through this review lncRNAs can mediate their
functions through interactions with proteins, RNA, DNA, or a combi-
nation of these. Furthermore, the function of lncRNAs can often be
dictated by their localization, sequence and/or secondary structure.
There are many categories and sub-categories of lncRNAs, but some of
the major classifications include: antisense [6], bi-directional [7], en-
hancer-associated [8], intergenic lncRNAs (lincRNAs) [9], pseudogenes
[10], while a full review of all classifications can be obtained from the
recent review by Jarroux et al. [11]. LncRNA function cannot be de-
termined simply based on the lncRNA classification. However, the
classification can sometimes provide insight into its mechanism of ac-
tion, such as antisense lncRNAs impacting their neighboring genes.
However, this same classification can also lead to erroneous assump-
tions about how the lncRNA regulates gene expression. Recently, some
lncRNAs have been demonstrated to actually encode small peptides
indicating that these genes are misclassified as noncoding, although it is
possible that they could also have functions as a noncoding RNA in
addition to their peptide coding capacity [12–17]. It is therefore, im-
portant to have a logical methodology to study the biological im-
portance of these genes.
The innate immune system functions as a rapid initial response
against specific pathogens, while also promoting the activation and
development of the adaptive immune system [18]. Macrophages and
dendritic cells are important innate immune cells that initiate the im-
mune response through recognition of specific pathogen-associated
molecular patterns (PAMPs) through their germline-encoded pattern
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recognition receptors (PRRs) [18]. These receptors couple pathogen-
sensing to activation of downstream signaling cascades resulting in up-
regulation of numerous inflammatory pathways [19]. While a robust
immune response is crucial for eliminating pathogens, prolonged acti-
vation can be detrimental to the host [20]. Not surprisingly, many as-
pects of the inflammatory response are tightly regulated at both tran-
scriptional and post-transcriptional levels allowing for a transient
antimicrobial response while subsequently promoting a return to
homeostasis [21]. Perturbations in this regulation can have significant
consequences that can manifest in diseases, such as arthritis [22],
multiple sclerosis [23] and cancer [20,24]. While the role of coding
genes in immune cell function has been well characterized, the role of
lncRNAs in these processes is just beginning to emerge [25] (Fig. 1).
Here, we use the biological model system of macrophage activation as a
framework to demonstrate how we approach the study of lncRNA
biology. We provide a step-by-step guide to consider when studying
lncRNAs. Furthermore, we discuss the challenges, as well as the
emergence of new technologies that are helping evolve the ways we
study these genes.
2. Getting started
2.1. The biological question
The lncRNA field is in its infancy yet from what we do know we find
that lncRNAs play critical roles in a wide variety of biological processes
and diseases from cell differentiation, tissue organ development, flow-
ering in plants, to cancer metastasis to name just a few [26–30]. We
believe that lncRNAs play regulatory roles in many biological processes
and diseases. Therefore, no matter what your research area is, there is a
rich source of information to be obtained from the study of lncRNAs in
your field of interest.
The bulk of lncRNA studies to date have focused on the cancer field
[31–33]. Meanwhile, studies of lncRNAs in the context of innate im-
munity have lagged, making up only ~4% of all lncRNA papers to date
(Fig. 1). The innate immune system provides one of the first lines of
defense against infection through the induction of inflammation
[34,35]. The inflammatory response of murine macrophages offers a
powerful system for applying genomic approaches for studying novel
lncRNAs within the framework of a pathway that has been studied for
decades. Macrophages are important mediators of inflammation and
initiate this response through recognition of specific pathogen-asso-
ciated molecular patterns (PAMPs) through their germline-encoded
pattern recognition receptors (PRRs). These receptors couple pathogen-
sensing to activation of downstream signaling cascades resulting in
activation of numerous transcription factors, including NF-kappaB (NF-
κB) and interferon regulatory factors (IRFs) that can act in combination
to both positively and negatively regulate the expression of thousands
of genes [36,37]. There are 10 different TLR genes in the human
genome and 13 TLR genes in mice [38–40], each binding a different
PAMP [41]. Using this extensively studied biological system, we iden-
tified the first example of a TLR-stimulated lncRNA, lincRNA-Cox2,
which was capable of positively and negatively regulating distinct types
of innate immune genes [42–46]. Knockdown of lincRNA-Cox2 resulted
in impaired production of proinflammatory genes (i.e., IL-6), while IFN-
related genes were hyperactivated in the absence of lincRNA-Cox2
[42–46]. Numerous other studies have made use of the TLR-signaling
biological system, uncovering and characterizing dozens of novel
lncRNAs that act in a wide range of mechanisms to either positively or
negatively regulate this pathway as reviewed in Carpenter et al. and
Hadjicharalambous et al. [47,48].
2.2. LncRNA candidate selection
As mentioned lncRNAs are categorized into five main classes of long
noncoding RNAs based on their genomic location: antisense, bidirec-
tional, intronic, enhancer-associated, and intergenic. Intergenic and
enhancer lncRNAs contain their own promoters and are distinct from
protein-coding genes. Bidirectional lncRNAs share a promoter and are
transcribed from the opposite strand of a protein-coding gene, while
intronic lncRNAs are transcribed within an intronic region of a protein-
coding gene (Fig. 2A) [49,50]. The specific class of lncRNAs can often
provide significant insight into how it may regulate gene expression.
For example, lncRNAs antisense to a coding gene have been
Fig. 1. LncRNA publications.
Graph representing the total number (black bar) or immunology related (pink bar) publications in the lncRNA field since 2010 to 2018.
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demonstrated to be involved in transcriptional interference, negatively
affecting the expression of their coding gene [51]. While all categories
of lncRNAs will no doubt be important in various biological processes,
the most targetable lncRNAs are intergenic lncRNAs. A benefit to
studying an intergenic lncRNA (lincRNA) is the immense variety of
molecular techniques that would not apply to other types of lncRNAs,
such as antisense, bidirectional and intronic lncRNAs, which often
overlap coding genes and their targeting could lead to possible un-
wanted interference of that coding gene.
2.2.1. Cis regulators
Numerous studies have established that lncRNAs can regulate the
expression of their neighboring coding genes (cis regulation) [51]. A
recent study by Engreitz et al. demonstrated that a significant portion of
lncRNAs had cis effects on their neighboring genes [52]. Interestingly,
in most cases, the cis effect did not require the production of the lncRNA
transcripts themselves, but instead required the processes associated
with their production, such as transcription and splicing [52]. There are
many examples of lncRNAs that regulate their neighboring coding
genes, for example: lnc-MARCKS, lnc-TNFAIP3, AS-IL1α, lnc-IL7R, and
IL-1β-eRNA [52–56]. Recently we used genetic mouse models to show
that lincRNA-Cox2 can function as an enhancer RNA in cis to regulate
its neighboring gene Ptgs2 [46]. For these reasons, one aspect to con-
sider when selecting a candidate, no matter the class, is to investigate
the effect of the transcriptional expression on neighboring coding
genes. This candidate selection approach is sometimes referred to as
“guilt by association” [57,58]. This bioinformatic approach drives an
initial hypothesis that the lncRNA could be involved in the similar
biological pathway as their neighboring protein-coding gene due to
their co-expression.
2.2.2. Trans regulators
A large number of studies to date have also shown that lncRNAs can
regulate gene expression on different chromosomes (trans regulation)
[59] (Fig. 2C). The majority of lncRNAs studied in immunity were in-
itially identified following RNA-sequencing to examine their expression
profiles in specific cell lines or tissues during inflammatory activation.
For example, lincRNA-Cox2 was initially identified as an up-regulated
lncRNA in murine dendritic cells following TLR4 stimulation [60], as
well as murine bone marrow derived macrophages (BMDMs) following
TLR2-depedent stimulation [42]. Studies have also highlighted the
functions of lncRNAs that are highly downregulated post inflammatory
activation, such as lincRNA-EPS [61] and lnc13 [62]. Both lincRNA-
Cox2 and lincRNA-EPS were discovered in BMDMs post TLR in-
flammatory activation and were chosen for further characterization
based on their extreme expression profile. LincRNA-Cox2 is rapidly
upregulated and regulates a large number of interferon stimulated
genes (ISGs) and NF-κB regulated genes [42]. Meanwhile, lincRNA-EPS
is rapidly down-regulated during inflammation and acts as an in-
flammatory brake on all ISGs during periods of homeostasis [61]. These
are just two examples of lncRNAs that have provided critical insights
into the roles of lncRNAs in immunity. For more information on specific
lncRNAs that are involved in innate immunity we direct you to the
following recent reviews on this topic [42,47,63]. In addition to these
bulk RNA sequencing studies, a small number of single cell RNA se-
quencing studies have been performed in both human and mouse that
can be utilized to examine differential expression of lncRNAs in basal
versus treatment conditions or between cell types [64–68]. Numerous
RNA-seq (both bulk and single cell) datasets are available for a variety
of primary cells, cell lines or tissues of interest either basally or under a
multitude of inflammatory or cellular differentiation treatments. These
datasets outlined in Table 1 [42,46,74–77, 57, 61, 64, 69–73] and
Table 2 [53,56, 82–90, 65–68, 78–81] provide a rich source of lncRNAs
for further investigation.
EVLncRNAs [91], NONCODE [92], or LNCipedia [93] are databases
that categorize published information on all annotated lncRNAs. These
databases can be utilized to determine if a lncRNA is experimentally
validated within one or more studies. Additionally, these databases can
provide information on whether a lncRNA possesses multiple isoforms,
secondary structure, cross-species conservation and/or disease-asso-
ciation via presence of single nucleotide polymorphisms (SNPs).
2.3. LncRNAs expression and specificity
Multiple studies have demonstrated that lncRNA expression is more
cell type specific compared to protein-coding genes [94–96]. Such
specific expression patterns can often provide important clues into the
specific biology that the gene could be involved in [46] (Tables 1 and
2). A variety of consortiums exist for both human and mouse and can be
utilized to determine cell type specificity of a lncRNA candidate further.
For instance, GTEx [97] and XENA [98] are two websites that include
RNA sequencing on healthy primary human tissue samples, in addition
to samples from patients with diagnosed cancers. This will further assist
the initial understanding of the expression of the lncRNA in specific
tissues as well as obtaining information on whether a lncRNA is in-
volved in cancer. In contrast, if a researcher is studying a mouse can-
didate lncRNA, the Mouse Cell Atlas (MCA) [99], as well as Tabula
Muris [100] are excellent tools to assess specificity in cellular expres-
sion, as well as differential splicing isoforms amongst differentiated cell
types. Additional websites for mouse and human expression datasets
can be found at the ENCODE project [101], the European Bioinfor-
matics Institute Expression and the FANTOM projects [102]. These sites
are filled with raw and analyzed data sets from either single cell or bulk
RNA sequencing from primary cells, tissues or immortalized cells ready
to use to determine the statistical significance of expression for any
annotated lncRNA candidate.
Fig. 2. Classification and regulation of LncRNAs.
(A) Positional classifications of lncRNAs based on their genomic location in respect to nearby protein coding genes: bidirectional, intergenic, antisense, antisense
intronic, sense intronic, enhancer, sense-overlapping. (B) The lower left panel of the figure represents how lncRNA activity can be regulated transcriptionally.
Transcriptional activation is depicted basally ‘Part I’, as well as during inflammatory activation ‘Part II’ following stimulation of a pattern recognition receptor (PRR).
Three lncRNA examples genes are shown A, B and C. Part III depicts how a lncRNA can undergo differential isoform expression which is regulated co-tran-
scriptionally. During active transcription a lncRNA can either undergo differential splicing or utilize a new transcriptional start site post inflammatory stimulation,
such as lipopolysaccharides (LPS). Post-transcriptional regulation of a lncRNA is broken up into three parts: IV, V and VI. After transcription is completed there is
several processes that a lncRNA can undergo. Part IV depicts RNA modifications, which can change the structure of a lncRNA molecule. These modifications can be
added or removed depending on the inflammatory state of a cell. Part V depicts the process of miRNA biogenesis, where a lncRNA can be processed to a mature
miRNA. Part VI shows that a lncRNA can also be translated if it has a small open reading frame (smORF). (C) The lower right panel of the figure illustrates the
regulatory function of a lncRNA in the nucleus and the cytoplasm. During active transcription (basally ‘Part I’ or inflammatory ‘Part II’), a lncRNA can function to
repress genes (mRNA gene A and C) or activate genes (mRNA gene A and B). A lncRNA can either be a scaffold for transcription factors to enhance activation, or a
scaffold for chromatin remodeler proteins to open or close chromatin. A lncRNA can also regulate a mRNA transcript co-transcriptionally ‘Part III’ by affecting either
the stability, change the splicing activity, editing of modifications, or even the capping of the mature mRNA. Finally, post-transcriptionally a lncRNA can function to
regulate the mRNA in several ways. A lncRNA can affect the stability of a mRNA transcript: ‘Part IV and Part V.’ Alternatively, a lncRNA can function as a miRNA
sponge which indirectly de-represses the expression of a mRNA that would be targeted by the miRNAs. Lastly, a lncRNA can modulate the translation of a mRNA by
binding to ribosomes or mRNA transcripts during translation.
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2.4. Determining disease association
Genome-wide association studies (GWAS) have revolutionized the
study of complex diseases by allowing quantitative disease-association
of thousands of genetic loci [103]. These studies include evaluation of
single-nucleotide polymorphisms (SNPs) or deletions and determina-
tion of their association with a disease phenotype. Diseases studied
range from Inflammatory Bowel Disease (IDB) to schizophrenia
[104,105]. Until recently, most GWAS studies focused on protein-
coding genes, even though 90% of disease-associated SNPs lie in non-
coding regions of the genome [106]. There are several databases that
summarize the plethora of published human sequencing studies, in-
cluding UK Biobank [107] and GWAS Catalog - EMBL-EBI [108]. Other
databases specifically focus on SNPs within lncRNAs, such as
lncRNASNP2 [109] and Lnc2Catlas [110].
To date, a couple of studies have clearly shown how SNPs from
GWAS studies can be used to identify clinically relevant lncRNAs.
Castellanos-Rubio et al. identified a SNP rs917997 associated with
Celiac Disease and showed it was located within a novel lncRNA, Lnc13
[62]. Lnc13 regulates inflammatory genes and mediates its function via
an interaction with an hnRNP protein [62]. Furthermore, they showed
that the SNP disrupted the RNA-protein interaction, thus making the
lncRNA dysfunctional [62]. Another fascinating study began by mining
GWAS for atherosclerosis disease-associated SNPs, which led to the
discovery of a novel lncRNA, LIN00305, that had 5 SNPs that were
associated with atherosclerosis all located within an intronic region
[111]. The group went on to characterize LINC00305 in human primary
and immortalized monocytes as a promoter of inflammation through
activating the aryl-hydrocarbon receptor repressor (AHRR) – NF-κB
pathway by directly binding to lipocalin-1 interacting membrane re-
ceptor (LIMR), acting as a scaffold to promote the interaction between
LIMR and AHRR [111]. Both of these studies started by investigating
clinically relevant SNPs that led to the discovery of disease-associated
lncRNAs, providing the groundwork for future studies on potential
biomarkers or the development of novel therapeutic targets for a
variety of inflammatory diseases.
Table 1
Murine sequencing datasets.
Type Treatment Duration (h) Sequencing PMID
Spleen Tissue TLR4 0, 6 RNA 30404006
Lung Tissue TLR4 0, 6 RNA 30404006
SARS-CoV 0, 24 RNA 27462873
PR8 0, 24, 48, 120 RNA 20978541
Monocyte FACs sorted – – RNA
ATAC
ChIP - H3K27Ac
ChIP - H3K4me1
ChIP - H3K4me2
ChIP - H3K4me3
24586061
Dendritic cells CD103+ PR8 0, 24, 48, 120 RNA 20978541
Bone marrow derived None – RNA 19182780
TLR1/2 0, 6
TLR4 0, 6
TLR9 0, 6
Macrophage Alveolar macrophage depletion NS1-GFP 0, 12 RNA 30886410
Bone marrow (monocyte) – – RNA
ATAC
ChIP-H3K4me1
ChIP-H3K4me3
ChIP-H3K27Ac
25480296
Lung tissue resident
Spleen tissue resident
Kupffer cells
Peritoneal macrophage
Colonic macrophage
Microglia
FACs Sorted – – RNA
ATAC
ChIP - H3K27Ac
ChIP - H3K4me1
ChIP - H3K4me2
ChIP - H3K4me3
25103404
Bone marrow derived TLR4 0, 0.25, 0.5, 1, 2 RNA
Chromatin, nucleus, cytoplasm
22817891
Mtb 0, 4, 12, 24, 48 RNA 29712924
IFNγ Mtb 0, 4, 12, 24, 48
IL4/IL13 Mtb 0, 4, 12, 24, 48
TLR1/2 0, 5 RNA 23907535
TLR4 0, 2, 6 RNA 27315481
TLR4 0, 2, 6 ATAC
TLR4 0, 1 ATAC 26924576
TLR1/2 0, 0.25, 0.5, 1, 2 RNA
TLR4 0, 0.25, 0.5, 1, 2 RNA
ChIP - SRF
ChIP - IRF3
ChIP - p65
TLR4 0, 1 ChIP - H3K27Ac
ChIP- HeK4me2
ChIP - PU.1
ChIP - Nrf2
ChIP - p65
ChIP - Smad3
ChIP - Fos
RNA
29779944
27462873
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Additionally, as previously mentioned, XENA or Lnc2Catlas are
databases that combine RNA sequencing of tissue samples from healthy
and cancer patients, these tools can also be adapted to assess age,
gender, tissue or even disease association of splice variants [98,110].
These disease-associated SNPs or splice variants will help guide further
studies to determine therapeutic or biomarker potential. In summary,
assessing disease association by a variety of databases can provide in-
sight into the function of a lncRNA [112].
2.5. Conservation of lncRNAs
Unlike lncRNAs, coding genes are highly conserved across distal and
related species. The requirement of coding genes to encode functional
peptides likely constrains the variation within the open reading frame
(ORF) sequence [113]. LncRNAs by definition are not translated and
often have poor sequence conservation across related species. Many
lncRNAs display species-specific expression. Thus, inferring function
based on sequence similarity is a challenge (reviewed in [114]). A more
useful conservation metric is to assess whether the lncRNAs have con-
servation of synteny (location relative to flanking coding genes), along
with expression conservation [115]. The databases LNCipedia and
NONCODE have user-friendly interfaces, allowing assessment of both
conservation of synteny and sequence for lncRNAs. Additionally, ex-
pression conservation can be useful to assess whether the specific
lncRNA has the same biological role in similar and divergent species
[116]. Conservation of lncRNA expression can also be indicative of
conservation of regulatory regions, such as transcription factor binding
sites within promoters [117]. However, conservation of expression does
not necessarily mean the RNA product is important for lncRNA func-
tion. Enhancer RNAs (eRNAs), for example, are thought to pre-
dominantly function by creating a localized, active transcriptional state,
which can activate neighboring genes [118–120]. It is unclear to what
extent the specific RNA sequence of eRNAs is important for their
function [118]. Nevertheless, a couple of studies have provided
Table 2
Human sequencing datasets.
Type Treatment Duration (h) Sequencing Reference
Spleen Tissue – – Bulk RNA
ChIP - H3K36me3
ChIP - H3K4me1
ChIP - H3K4me3
26030523
Lung Tissue – – Bulk RNA
ChIP - H3K36me3
ChIP - H3K4me1
ChIP - H3K4me3
26030523
Liver Tissue – – Single cell RNA 30348985
B cell Lymphoblastoid cell line TNF 6 ChIP - NFkB 30361341
*GSE31477*
PBMCs Healthy Influenza 0, 8, 16 Bulk RNA 25814066
IRF7−/−
UNC93−/−
Blood Healthy Longitudinal study Bulk RNA 22675550, 30962246
SLE
Macrophages Salmonella/Listeria 0, 2, 24 Bulk RNA 27690314
Monocytes TLR4 0, 1, 4 Bulk RNA 25855049
(Blood) CD14+ – – ChIP - H3K4me3 25258085
– – ChIP - H3K27me3
– – Bulk RNA
(Blood) CD14+ CD16+ – –
Monocytes (PBMCs) – 0, 4 ChIP-H3K4me3 22675550, 28900427
– 0, 4 ChIP-H3K27Ac
Uninfected – Bulk RNA
Influenza, S. aureus, S. pneumoniae, E. coli – Bulk RNA
LPS 0, 4, 24 Bulk RNA
Monocyte bead purification LPS 0, 4, 24, 144 Bulk RNA 27863248
ChIP-H3K4me1
ChIP-H3K27Ac
β-Glucan 0, 4, 24, 144 Bulk RNA
ChIP-H3K4me1
ChIP-H3K27Ac
Dendritic cells (Blood) CD141+ – – Bulk RNA 28475900
(Blood) CD1c+
Plasmacytoid CpG-C 0, 1, 2 Single cell RNA 30127440
Monocyte derived Differentiation – RNA bulk 24744378
Differentiation – ChIP - H3K27Ac
Differentiation – ChIP - STAT1
Differentiation – ChIP - IRF1
A. fumigatus 0, 6 Bulk RNA 28280489
C. albicans 0, 6 Bulk RNA
TLR4 (LPS) 0, 6 Bulk RNA
Macrophages THP-1 (PMA) Mtb 0, 4, 18, 48 Bulk RNA 22675550
TLR1/2 0, 8 Bulk RNA 24371310
TLR1/2 0, 8 Bulk RNA 30918008
TLR2/6 0, 8
TLR4 0, 8
Monocyte derived – – Bulk RNA 29475453
Mtb 0, 24 Single cell RNA 28192419
H1N1 0, 1, 3, 6 Bulk RNA 29475453
N5N1 0, 1, 3, 6 Bulk RNA
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examples of eRNAs for which the transcript sequence was necessary for
their function [121,122].
To further investigate conservation of a candidate, BLAST (basic
local alignment search tool) on NCBI (national center for biotechnology
information) can be utilized to explore conservation across species
[123] or lncRNAdb v2.0 [124], by inputting the entire sequence of a
lncRNA of interest. If a lncRNA has a known structure, inputting the
shorter structured RNA sequence can enhance conservation results. One
can also, view the conservation track of the UCSC genome browser
[125] to assess if this specific sequence within the lncRNA transcript is
conserved across species. In summary, conservation of a lncRNA is
complicated to assess using current bioinformatic methods. However,
understanding if there is a functional motif (therefore a shorter starting
input sequence) within a lncRNA can allow for an increased assessment
of functional conservation across species.
2.6. Transcriptional regulation of lncRNAs
Activation of inflammatory pathways result in both up and down
regulation of specific lncRNAs, which in turn can have either positive or
negative regulatory effects on the pathway, such as activation of se-
questered transcription factors [45,126] or enhanced or repressed ex-
pression of specific inflammatory cytokines [61,84,127]. Genes that are
immediate regulators of immunity are poised for transcriptional acti-
vation, which can be assessed by defining the openness of promoter
regions of a lncRNA pre- and post- inflammatory stimulation. Common
methods for assessing chromatin accessibility of promoters include
DNase-hyper-sensitivity (DNAseHS) [128] and the Assay for Transpo-
sase-Accessible Chromatin (ATAC) [129]. DNAse HS-seq and ATAC-seq
datasets are available from a variety of tissues on ENCODE for both
mouse and humans (Tables 1 and 2). If the promoter is open (acces-
sible), this is indicative of either a poised or actively transcribed gene.
Accessibility of promoter regions in the hematopoietic cell lineage was
assessed by Lara-Astiaso et al. through performing ATAC-seq for all
cells in the hematopoietic lineage [76]. This dataset provides insight
into a gene's promoter accessibility, as well as cell type specificity. For
instance, if the promoter is open in all cell types, it shows that it is
ubiquitously accessible and possibly expressed, while if a promoter is
only accessible in myeloid cells or terminally differentiated macro-
phages this provides insight into the cell type that could be most bio-
logically relevant for a particular lncRNA. Another interesting data set
from Tong et al. have provided ATAC sequencing from bone marrow
derived macrophages (BMDMs) pre- and post- inflammatory time
course stimulation [72]. This dataset assesses both poised genes and
genes that undergo promoter remodeling during inflammatory activa-
tion. If a promoter of a lncRNA is inaccessible or accessible during in-
flammatory stimulation, this could provide insight to its regulation and
biological significance during an immune response.
Once the accessibility of a promoter region is determined, defining
post-translational modifications of histones on promoter regions will
assess promoter activity in specific cell types or inflammatory states
[130–132]. A histone modification is a covalent post-translational
modification (PTM) to histone proteins which includes methylation,
phosphorylation, acetylation, ubiquitylation, and sumoylation (re-
viewed in [133]). Posttranslational histone modifications do not affect
DNA nucleotide sequence but can modify chromatin availability to the
transcriptional machinery [134]. Identifying the types of epigenetic
histone marks will add additional layers of understanding if the can-
didate is active, poised, silenced or an enhancer. Many publicly avail-
able datasets provide this information outlined in Tables 1 and 2. While
the examples we outlined here are immune focused there is a vast array
of additional primary and immortalized cell line for every histone mark
available through the easily accessible ENCODE database [101].
Finally, the transcriptional regulation of a lncRNA can be defined by
analyzing the transcription factor (TF) motif's that lie within the pre-
dicted promoter region [135–137]. RNAReg2.0 [138] or HOMER
[139,140] are useful tools to predict TF binding sites by motif analysis.
TF motifs can be indicative of biological pathway regulation indicating
when a gene is expressed. These findings of predicted TF can then be
put into a gene ontology tool (PANTHER or DAVID) to assess how a
candidate lncRNA is transcriptionally regulated. For instance, the pre-
sence of pioneering transcription factors could provide information on
the cell type specificity of a lncRNA. On the other hand, if the promoter
motifs are enriched for p65, Interferon Response Factors (IRFs) or Ac-
tivating Transcription Factors (ATFs) this would be indicative of in-
flammatory specific expression. This finding can be further supported
by Chromatin immunoprecipitation (ChIP) sequencing data sets from a
multitude of labs, as well as data from the ENCODE project (outlined in
Tables 1 and 2).
3. Functional characterization of lncRNAs
3.1. Assessing whether lncRNAs are translated
The categorization of lncRNAs as “noncoding” is initially de-
termined bioinformatically using the arbitrary cut-off of< 100 codons
[141]. This leaves the possibility that some lncRNAs may be mRNAs.
Therefore, one of the first steps in characterizing a candidate lncRNA is
to confirm that it is noncoding. For example, in Drosophila, a gene
annotated as a lncRNA FBgn0087003, was shown to encode multiple
small ~ ten amino acid peptides critical for development [142]. The
discovery of these germline-encoded biologically active peptides has
opened the door into new and exciting levels of regulation. However,
this discovery also shows that we should be cautious when character-
izing a lncRNA to confirm that indeed they are noncoding.
Several bioinformatic tools exist for predicting small ORFs (smORF)
but have noted that the predictive ability for smaller ORF size is in
general very poor [143]. PhyloCSF uses codon substitution frequency,
together with conservation across multiple species, to provide a score
metric that can be used to determine the presence of a conserved ORF
[113]. Other approaches have sought to identify novel small peptides
using mass spectrometry. However, a major challenge is determining
whether the peptides identified correspond to novel smORFs or re-
present degraded intermediates of larger proteins [144].
The development of ribosomal foot-printing coupled to next-gen-
eration sequencing (ribo-seq) has provided a powerful quantitative
method for assessing global translation [145,146]. While ribosome
profiling allows for ribosome nuclease-protected RNA fragments to be
mapped to transcripts to enable quantitative measurement of the
translation efficiency [146]. In addition, to mapping ORFs, ribo-seq can
be performed with a drug that stalls ribosomes at the start codon to
globally map translation start sites—this revealed significant numbers
of non-canonical translation initiation from CTG codons [146]. Ribo-
seq has also found that many lncRNAs appear to be translated, raising
the possibility that some of these transcripts could be producing small
peptides [145]. Guttman et al. developed the ribosome release score
metric as part of the ribosome profiling analysis pipeline to more ac-
curately predict translational efficiency. Their findings show that ri-
bosome occupancy of lncRNAs and 5′UTRs does not always equate to
translation [147]. Furthermore, Guttman et al. concluded that most
noncoding transcripts are not translated into peptides. Several addi-
tional studies have examined lncRNAs binding to ribosomes and have
concluded that ribosome binding may not be functional and may serve
as a quality control process to degrade transcripts with low coding
potential via the nonsense-mediated decay (NMD) pathway [148,149].
A recent study by Jackson et al. used ribo-tagging in LPS-stimulated
mouse macrophages to identify ribosome footprints within hundreds of
annotated lncRNAs, raising the possibility that they may be producing
functional peptides [150]. They characterized an 83aa peptide located
within a previously annotated lncRNA Aw112010 and showed it was
produced by non-canonical “CTG” translation initiation [150]. They
demonstrated that this small peptide had a critical role in mucosal
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immunity in mice and was specifically required for the expression of
Il12 mRNA [150]. The exact mechanism of how this peptide drives Il12
expression is yet to be elucidated.
4. LncRNA expression manipulation
4.1. RNA interference (RNAi)
The laborious process of functionally characterizing lncRNAs has
remained a major limitation to lncRNA functional discovery. For ex-
ample, while ~16,000 long noncoding RNAs (lncRNAs) have been
identified in the human genome, only 3% of all validated lncRNAs have
an ascribed function [47,91,151]. For more than two decades since its
discovery, RNA interference (RNAi) has been the method of choice for
loss of function studies. The ease and versatility of RNAi make it ap-
pealing for use, requiring short complementary small RNAs transfected
into cells that can then utilize the endogenous cellular machinery to
target specific transcripts [152,153] (Fig. 3A). Additionally, short
hairpin RNAs (shRNAs) can be expressed in a lentiviral context to
accomplish stable RNAi in cells [154]. RNAi is most active in the cy-
toplasm, which makes it most useful for targeting mRNAs and lncRNAs
that reside in the cytoplasm [155]. Success in knocking down some
lncRNAs, for example lincRNA-Cox2, has been attributed to the fact
that this lncRNA is expressed both in the cytoplasm and the nucleus
(perhaps cycling between both compartments) and hence is susceptible
to RNAi [42]. However, many lncRNAs are thought to be nuclear-re-
stricted where RNAi has been demonstrated to have limited efficiency
[156] (Fig. 3).
4.2. Antisense oligonucleotides (ASOs)
Antisense oligonucleotides (ASOs) can be either RNA or DNA-based
and can be used to target complementary sequences within a transcript.
Unlike RNAi, ASOs do not engage the cellular RNAi machinery [157].
Instead, ASOs function by hybridizing to the target RNA and inhibiting
its function by either inducing the RNase H pathway or by steric in-
hibition. The RNase H enzyme is part of a cellular pathway that nor-
mally functions to resolve unwanted DNA: RNA interactions that can
Fig. 3. LncRNA expression manipulation.
(A) RNA interference acts post-translationally, degrading transcripts in the cytoplasm. (B) Gapmers, are composed of RNA and core stretch of ~10 nt of DNA
sequence that is critical for engaging the RNase H pathway. (C) CRISPRi uses a catalytic inactive version of Cas9 fused to a KRAB domain. The CRISPRi system can
target transcription start sites (TSS) to induce heterochromatin-based transcriptional silencing. CRISPR/Cas9 can be used to target (D) splice sites or (E) to delete
specific regions of lncRNA loci using two flanking gRNAs. (F) Polyadenylation signals (3–5) can be inserted just downstream of the TSS, which result in premature
termination of transcription. These poly(A) signals can be flanked by loxP sites to allow their removal. (G) The CRISPRa system can target transcription start sites
(TSS) to induce transcriptional activation. (H) LncRNA sequences (cDNA) can be cloned into plasmid either with native promoter or a constitutively active promoter
(i.e. EF1a, CMV). The different tools are compared base on criteria described in the subheadings of each column. ‘Target’ describes what aspects of the lncRNA's gene
expression are targeted, for example transcriptional (CRISPRi, C) or posttranscriptional silencing (RNAi, A). ‘Reversible loss-of-function?’ is the silencing effect of this
tool reversible in a cell? In general, only the nuclease active Cas9 activity (D) is not reversible since the regions of the loci are actually deleted. ‘Type of phenotype’
refers to whether the tool completely shuts off expression of the lncRNAs. Hypomorphic refers to the fact that some level of expression remains despite the level of
knock-down. Only compete removal of the locus completely abolishes its expression. Knock-down of nuclear lncRNAs? Touches on the observation made by many
groups, which have demonstrated that RNAi is not very active in the nuclear (in contrast to the other technology). ‘Time to phenotype’ refers to the amount of time
from planning experiment to obtaining phenotype. Short: transfection of RNAi and ASO (A and B) remain the quickest route to phenotype since they don't require
cloning or modification to the cell. Medium: CRISPRi/a (C, G) requires design and cloning guide RNAs to a specific locus in addition to generation of a functional
CRISPRi/a cell line. Medium/Long: Both CRISPR mediated deletions and adding poly(A) signal (D and E) require screening for cells (making single cell clones) to
identify those with successful modifications.
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occur during replication and/or transcription [158]. One of the most
widely used types of ASOs for targeting lncRNAs are gapmers which
contain a “hybrid” modified/unmodified configuration consisting of
~10 nt DNA core flanked by 2′-O-Methyl or LNA-modified synthetic
nucleotides (Fig. 3B). Gapmers offer the benefit of modifications for
stability and reduced toxicity, while still allowing engagement of the
RNase H pathway (Fig. 3B) [159].
Efficient depletion of nuclear lncRNAs has been demonstrated using
modified DNA anti-sense oligonucleotides [155]. Ilott et al. used gap-
mers to successfully knock-down TLR-induced enhancer RNA, as they
were unable to knock-down these same eRNAs with 4 different siRNAs
[56]. Recent in vivo applications for DNA oligonucleotides have also
proven successful as a possible treatment of a neural degenerative
disease called Angelman's syndrome. Angelman's syndrome is a
monogenic disorder caused by mutations in the E3 ubiquitin ligase 3A
(UBE3A) [160,161]. As UBE3A is a paternally-imprinted gene, a mu-
tation in the maternal allele is sufficient to lead to disease [160,161].
Paternal imprinting of UBE3A requires the expression of an antisense
lncRNA called UBE3A-ATS. Therefore, targeting the paternal lncRNAs
UBE3A-ATS using ASOs leads to de-repression of expression of paternal
UBE3A, allowing the rescue of the defective maternal copy [161]. In a
mouse model, they showed that even partial restoration of the UBE3A
protein expression ameliorated some cognitive deficits associated with
the disease [161].
Mechanistically, it is important to dissect what features of a lncRNA
are important for its function — for example, determining whether the
lncRNA transcript is required or whether the mere act of transcription is
the important feature needed to mediate its function (discussed further
below). siRNAs and ASOs are thought to inhibit gene expression at the
posttranscriptional level, albeit by different mechanisms [162,163].
Nevertheless, there are examples of siRNAs (reviewed in [164]) med-
iating transcriptional inhibition. Targeting sequences near the 5′ end of
the transcript can induce the “torpedo-effect,” resulting in pre-mature
termination of transcription [165,166]. Therefore, when targeting
lncRNAs with ASOs or siRNAs, it's important to consider where along
with the transcript you are targeting to ensure biological interpretation
of the ablation is correct.
4.3. CRISPR/Cas technology
The introduction of CRISPR/Cas9 technology has revolutionized the
field of functional genomics by providing a novel tool for interrogating
gene function. CRISPR/Cas9 is a deoxyribose nuclease (DNase) that can
be specifically targeted to genomic regions via a guide RNA (gRNA)
[167,168]. Targeting of Cas9 to a region results in a blunt double-
stranded DNA break that engages the cellular Non-Homologous End-
Joining (NHEJ) DNA repair pathway, which promotes imprecise repair,
yielding small deletions in the repaired sequence. These small deletions
result in a frame-shift that disrupts the ORFs within coding genes,
thereby disrupting protein synthesis. LncRNAs do not contain ORFs and
span tens of kilobases of sequence in size. As such, targeting them with
a single gRNA is thought to be insufficient to disrupt their function
[169]. An alternative application of Cas9 that has proven effective for
targeting lncRNAs involves using two gRNAs flanking the lncRNA re-
gion of interest to induce deletion of the entire locus (Fig. 3E). The main
advantage of deleting lncRNAs is obtaining complete loss-of-function,
as demonstrated in a recent study that performed a CRISPR-mediated
deletion-screen to identify lncRNAs that positively and negatively reg-
ulate cancer growth [170]. On the other hand, deletion of the DNA
sequence may result in an inability to resolve whether a phenotype is
due to loss of lncRNA production or loss of DNA sequence (discussed
below) [171]. In an alternative approach, Liu and colleagues recently
performed a CRISPR screen targeting the splice sites of over 10-thou-
sand lncRNAs and identified 230 lncRNAs that proved essential for
viability (Fig. 3D) [172]. Targeting of splice sites has also been shown
to induce exon skipping within coding genes [173]. LncRNAs have
many of the same regulatory elements as coding genes. Hence future
studies may opt to target TF binding sites, secondary structure and/or
polyadenylation sites as a way to more finely dissect the functional
portions of lncRNAs.
The ease in which Cas9 can be targeted to specific genomic regions
sparked the development of a modified (catalytically inactivated) ver-
sion of the protein fused to the KRAB (Krüppel associated box) chro-
matin-silencing domain termed CRISPRi [174,175] (Fig. 3C). CRISPRi
can be used to target both coding and noncoding genes (such as
lncRNAs), triggering localized heterochromatin-silencing at the tran-
scription start site (TSS) [176]. Unlike RNAi, the transcription-based
inhibition by CRISPRi offers the ability to efficiently target lncRNAs
regardless of their localization in the cell. Gilbert et al. have shown
maximum knock-down efficiency when targeting regions +50 to +500
nucleotides relative to the transcription start site (TSS) [174]. However,
CRISPRi is limited by the availability of an accurately annotated TSS,
particularly for lncRNAs. Incorporating CAGE-seq, Gro-seq and/or
ChIP-seq data into gRNA design may improve efficient targeting of a
lncRNA of interest [177]. Nevertheless, a recent study from the
Weissman and Lim groups utilized CRISPRi to target 16,401 lncRNA
loci in 7 diverse cell lines and identified hundreds of lncRNAs required
for cell growth [96]. Therefore, despite its caveats, it appears that
CRISPRi can be a useful and powerful tool for interrogating lncRNA
biology.
An alternative approach to gene ablation is overexpression, gain-of-
function. Plasmid-based overexpression systems have been used for
decades to overexpress specific coding genes [178]. Plasmid-based
over-expression of lncRNAs is possible but is limited by the size (max
size: 6-8 kb) of the specific lncRNA (unpublished observations). How-
ever, because lncRNAs can function in cis, it's important that there is the
significant mechanistic characterization of the candidate lncRNA to
justify its cloning into a plasmid.
The same catalytically inactivated Cas9 has also been fused to a
transcriptional activation domain, for example, the VP16, a strong
transcriptional activator derived from herpesviruses [179,180]. This
strategy allows CRISPR-based transcriptional gene activation that can
be used to study gain-of-function phenotypes. The Zhang group recently
performed a CRISPR activation screen targeting over 10-thousand
lncRNAs [181]. They identified 11 lncRNAs that upon activation,
mediated BRAF inhibitor resistance in melanoma cells [181]. One of the
advantages of using a CRISPRa library is that the same library can be
used across different cell types, which makes it more cost effective.
Nevertheless, several caveats to the CRISPRa system, include the pos-
sibility that high expression of lncRNAs may create non-physiological
conditions leading to incorrect conclusions of specific biology.
LncRNAs have been shown to mediate functions via binding to
specific proteins. Hence over-expression of lncRNAs, without its protein
partner, may result in the inability to identify important biology. In
conclusion, it's important to understand the advantages and dis-
advantages of the loss- or gain-of-function methods used to modulate
lncRNA expression. All methods have their caveats, and these are im-
portant to consider when deciding which method to use.
4.4. Dissecting the complex functions of lncRNAs in vivo
LncRNAs can span large stretches of DNA sequence and can contain
important regulatory regions, such as enhancers, that are functionally
independent of the lncRNA product [182]. LncRNA promoters have
been proposed to also function as enhancers, promoting the recruitment
of transcriptional-activating factors that can affect the local nucleosome
environment and ultimately the expression of neighboring genes
[118,183,184]. Nevertheless, in vivo assessment of lncRNA function has
predominantly relied on assessing the consequence of deleting entire
lncRNA loci [171,185]. Numerous studies involving deletion of lncRNA
loci have been unable to rescue the deletion phenotype using a trans-
gene approach, making it difficult to attribute the phenotype to the
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lncRNA product itself [186,187]. While deleting the entire lncRNA is a
useful first step to establish a phenotype, this approach can make it
difficult to identify which component of the lncRNA is important for the
observed phenotype [171,185,188–190].
There are many approaches to generating a lncRNA knockout/
knockdown mouse. For instance, the complete knockout is the easiest
first step to take, which can be designed to remove the entire gene.
After this approach, one can use a more fine-tuned approach to reveal
exactly how the gene is working, including deleting specific regions of
the gene or inserting a poly-adenylation cassette before the exon1 of the
gene. A well-documented example of this phenomena is Fendrr, which
was shown to have a lethal phenotype in two independent studies, but
the importance of the lncRNA in development differed due to the mouse
ablation strategy. One in vivo study generated a knockout mouse by
removing the genomic loci completely and replacing it with LacZ while
leaving the native promoter intact [185]. This study identified Fendrr as
a key regulator of lung development and mesenchymal differentiation.
However this study did not attempt to rescue the ablated Fendrr allele
via a transgene [185]. An additional group generated a Fendrr knock-
down mouse using an alternative approach. Instead of disrupting the
chromatin architecture or removing any possible DNA enhancer re-
gions, they inhibited the transcription of Fendrr through the insertion of
a poly-A cassette into exon1 [191]. Using this lncRNA knockdown
mouse design, the scientists determined that loss of Fendrr led to heart
and body wall defects, which is slightly different from the phenotype in
the KO mouse study. Importantly, the heart and body wall defects
caused by the terminator insertion were rescued by a transgene of
Fendrr in vivo, further confirming that the phenotype is due to the RNA
while the KO phenotype could be due elements within the genomic
DNA [191]. Fendrr is located ~4 kb downstream of Foxf1 and ~12 kb
upstream of Irf8. The observed phenotype of the KO mouse is possibly
due to the deletion of an enhancer element that could impact the ex-
pression of protein-coding genes, which could have roles in lung de-
velopment [192,193].
We recently used multiple genetic mouse models to dissect both cis
and trans functions of lincRNA-Cox2 in vivo [46]. Working with a
complete lincRNA-Cox2 knockout [185], in which the gene is replaced
with a LacZ cassette, we observed a strong cis defect on the neighboring
protein-coding gene Ptgs2. From these studies, we concluded that
lincRNA-Cox2 functions in cis through an enhancer RNA mechanism to
regulate its neighboring gene Ptgs2 [46]. In order to determine how
lincRNA-Cox2 functions in trans to regulate genes independent of its cis
effects, we generated a mutant/intronless mouse by targeting the splice
sites of lincRNA-Cox2 using CRISPR/Cas9. This mouse represents a
knockdown mouse, and because there is a low level of transcription of
lincRNA-Cox2, Ptgs2 levels are the same as WT. LincRNA-Cox2 is not
inducible in the mutant mouse, probably because of transcript in-
stability due to the lack of splicing, enabling us to study its trans reg-
ulatory roles. Similar to our early in vitro work we observed using an
LPS shock model that many genes are both up and downregulated in the
serum of mutant mice indicating that lincRNA-Cox2 can indeed func-
tion in trans to regulate immune genes in vivo [46].
To prove genetically that a lncRNA is functioning in trans, a trans
rescue experiment can be performed using transgenic mice that con-
stitutively express a lncRNA. This rescue strategy has been utilized in
some studies including Evf2 [194,195], Jpx [196], as well as Pnky [197]
which both demonstrate successful rescue experiments where the
phenotype from germline ablation of a lncRNA is rescued through
generation and crossing with a transgenic animal.
5. Understanding the mechanism of action of a lncRNA
5.1. Subcellular localization and binding partners
LncRNAs are immensely adaptable molecules that are capable of
working through RNA-RNA, RNA-DNA, or RNA-protein interactions.
RNA-directed technologies such as Chromatin Isolation by RNA
Purification (ChIRP) [198,199] or RNA antisense purification (RAP)
[200,201], will help uncover lncRNA interactomes for RNA, genomic or
protein partners for highly expressed candidates. If a candidate is lowly
expressed, one can exogenously introduce a biotinylated form of the
lncRNA using the RNA pull-down method, which we have successfully
used to identify binding partners for lincRNA-Cox2. This has been
performed for many lncRNAs [42,202,203].
Functions of lncRNAs are associated with their subcellular fates.
Web servers can assist in quickly assessing experimentally determined
or predictive RNA-RNA interactions [204] or even RNA-protein inter-
actions [205,206]. Depending on the subcellular or extracellular com-
partmental localization of a lncRNA, this patterning will elude to the
regulatory role of the gene, as well as how a lncRNA might execute its
function [207–209]. Some LncRNAs that are localized to the nucleus or
chromatin have been experimentally shown to function in cis to regulate
the transcriptional expression of a neighboring gene, or in trans to
regulate the transcriptional regulation of a subclass of genes through
the interactions between heterogeneous nuclear ribonucleoproteins
(hnRNPs) [42,54,60,210]. In the cytosol, some lncRNAs have been
shown to interact with RNAs and proteins to carry out their molecular
functions [42,79,211,212].
Cellular localization of lncRNAs can be predicted using a publicly
available user-friendly web server established at http://lin-group.cn/
server/iLoc-LncRNA [213]. This can be the first step by a researcher to
attempt to predict the localization of your candidate based off of its
sequence. iLoc-LncRNA predicts subcellular location of a lncRNA by
utilizing the 8-tuple nucleotide features into the general PseKNC
(Pseudo K-tuple Nucleotide Composition) and rigorous tests show the
overall accuracy achieved by the new predictor is 86.72%, which is
over 20% better than previous algorithms [213]. In addition to pre-
diction methods, there are also publicly available sequencing datasets
that have performed RNA sequencing on fractionated cells. Bhatt et al.
utilized murine bone marrow derived macrophages, with and without
inflammatory stimulation, and fractionated these cells into chromatin,
nuclear, and cytoplasmic compartment to determine RNA localization
[74]. This data set can now be utilized to investigate the localization of
any murine candidate expressed in macrophages. A recent study took
this question a step further by performing RNA sequencing on nine
separate locations with a cell including: nucleus, nucleolus, nuclear
lamina, nuclear pore, cytosol, endoplasmic reticulum membrane
(ERM), outer mitochondrial membrane (OMM), mitochondrial matrix
(MITO), and endoplasmic reticulum lumen [214]. This exciting study
utilized an APEX-sequencing method, where the peroxidase enzyme
APEX2 was localized to these nine separate locations in nine separate
Human embryonic kidney (HEK) 293T cell lines. APEX2 can biotinylate
nearby RNA molecules allowing for streptavidin-based im-
munoprecipitation and RNA sequencing. The APEX-seq datasets will
provide a powerful resource for referencing localization of specific
lncRNA candidates that are expressed in HEK293T cells [214].
There are a few commonly used experimental approaches that can
be used to validate and determine the localization of a lncRNA.
Subcellular chromatin, nuclear and cytoplasmic fractionations of any
primary or immortalized cells can be prepared using previously pub-
lished procedures [74,215], followed by RNA isolation and RT-qPCR to
assess the localization. If additional compartmental fractionation is
desired other compartments can be enriched, such as mitochondria
[216,217]. Another standard gold technique is to visually determine
cellular localization by RNA FISH [42]. RNA localization can also be
directly visualized by microscopy [218]. SeqFISH techniques have re-
cently been pioneered for imaging thousands of cellular RNAs at once
using barcoded oligonucleotides [219]. The drawbacks of these in-situ
fluorescence hybridization (FISH) based approaches, however, are the
need for cell fixation and permeabilization, which can re-localize or
extract cellular components [220]. In addition to the difficulty of as-
signing RNAs to specific organelles or cellular landmarks due to spatial
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resolution limits, some of these difficulties can be overcome with the
addition of stains for markers of specific organelles.
5.2. Determining structure or motifs within a lncRNA
Conventionally, lncRNAs display poor sequence conservation across
species, with the exception of finite regions of conserved bases sur-
rounded by large seemingly unconstrained sequences [221]. While se-
quence conservation does not constrain lncRNA genes, lncRNA function
is found to be conserved across species when identifying motifs or
structure. A great example of this phenomena is represented in the
study of human maternally expressed gene 3 (MEG3), which utilized
the computer program mfold and multiple ex vivo and in vitro chemical
probing techniques to identify common motifs critical for retained
function in orangutan, rat, mouse and pig [222,223]. Another study
highlighting the marsupial Rsx lncRNA was initially found to have no
linear sequence similarity with the lncRNA Xist. However, it shared
substantial levels of non-linear conservation within k-mer repeats that
share functionally analogous protein-binding domains [224]. Publicly
available web servers can be utilized to determine the RNA structure of
a lncRNA depending on the size. The caveats to these web servers are
they do not work efficiently with large transcripts. To overcome this,
one can attempt to identify the critical sequence within the lncRNA that
could be functional using RIP-sequencing databases, which allow you to
input a gene ID to identify possible RNA binding proteins (RBPs). Ad-
ditionally, if a lncRNA has already been identified to bind to a protein
(s), RIP-sequencing databases can elucidate the specific binding loca-
tion(s). Knowing the location of RNA-protein interaction narrows down
the sequence input, that can be used for many web servers, which could
enhance the elucidation of a predictive structure. If there is no in-
formation about potential protein binding partners, then these RNA
structure webservers will be of little use.
An alternative approach to further investigate structure is to utilize
bioinformatic tools which now include parameters for covariation.
Covariation analysis identifies the positions in an RNA molecule that
have similar patterns of variation and the purpose of this covariance is
due to structural constraints initially shown for ribosomal RNA [225]
and now also for lncRNAs [123,226]. This study predicts structures for
MALAT1, using over 130 vertebrate sequences, as well as lncRNAs
RepA and HOTAIR [227]. These powerful tools allow scientists to
predict structures in an RNA molecule based on covariance, which in
turn drive the next steps of experimentally validating these findings.
Fortunately, there are several in vitro and in vivo experimental
techniques used to assess RNA structure for any size, even up to
17,000 nt (XIST). Dimethyl sulfate (DMS) probing uses a base-specific
reagent that can bind and alter the methylation state of unpaired ade-
nosine and cytosine nucleotides [228,229]. DMS “footprinting” is op-
timized for structural analysis of RNA. Protein binding to RNA will
generate a “footprint” that can be traced due to alterations in the RNA
structure. The transcript size that can be evaluated is rather small
(< 500 nt) but this method can be performed both in vitro and in vivo as
DMS can easily penetrate the cell membrane, shown to work for
lncRNAs from 590 nt, Braveheart (Brvht) [230]. Xue et al. utilized DMS
and SHAPE to determine the multiple smaller order structures of Brvht,
including an AGIL motif and a 90-degree turn [231]. This AGIL motif is
critical for transcription factor binding, which specifies the cardiovas-
cular lineage. Targeting Structure-Seq relies on RNA methylation by
DMA being performed in vivo. Using this method, structural models of
elements within Xist were developed [232]. SHAPE (selective 2′hy-
droxyl acylation by primer extension), as well as the modified SHAPE-
MaP [233], In-cell SHAPE-Seq [234] and icSHAPE-seq [235], can in-
terrogate the RNA structure both in vitro and in vivo using the chemical
NMIA and its derivatives to detect flexible regions in RNA secondary
structure [236,237]. This method has been proven valuable for Xist
[238], RepA [239], and Rox1/2 [240]. PARIS (psoralen analysis of RNA
interactions and structures) was recently developed to determine both
RNA structure and interactions in vivo [241]. Using this approach, a
model for the higher order structure of Xist was interrogated [241].
These approaches are critical for identifying structural motifs and en-
hance conservation studies, as well as these identified elements, can be
used as novel targets for further exploration in precise intervention
suitable for therapeutic applications.
5.3. Alternative splicing of lncRNAs
Alternative splicing (AS) significantly impacts the diversity of RNA
isoforms produced, which in turn impacts the protein isoforms pro-
duced and can affect many aspects of the protein's biology including
binding, intracellular localization, enzymatic activity, stability, post-
translational modifications [242]. AS also impacts lncRNA genes which
can have multiple isoforms depending on the cell/tissue, age, and dis-
ease state [243–245]. The UCSC genome browser [125], as well as
NONCODEV5 [92], have all the annotated isoform transcripts for each
gene. These tools will identify annotated transcript isoforms while RNA
sequencing will provide information on which of these splicing events is
utilized in a given cell or biological state. To date, there have only been
a small number of papers focusing on the role that alternative splicing
plays in controlling the immune system. One recent global study has
shown that widespread shortening of 3′ untranslated regions and in-
creased exon inclusion are evolutionarily conserved features of innate
immune responses in primary human macrophages following Listeria
monocytogenes and Salmonella typhimurium infection [78]. This is a
transformative study for mRNAs but can be reanalyzed to examine AS
and possible contributions from lncRNAs.
Publicly available tools for tissue isoform expression specificity is
available on GTEx [97] and XENA [98] for human genes. Tabula Muris
[100], a murine specific dataset, is now available as a UCSC genome
browser track on mm10 and can be used to view cell-type specific
splicing events and isoform expression. In order to identify isoforms in
illumina RNA sequencing datasets, several tools can be utilized. MISO
(Mixture of Isoforms) is software for a probabilistic model for RNA seq
will identify specific the 5′ splice sites used for each isoform [246]. Two
other tools highly used for splicing analysis are JuncBASE [247],
MAJIQ-SPEL [248], and DRIMSeq [249]. These tools can be used to
define if your candidate gene undergoes any alternative splicing (al-
ternative start site, exon inclusion/exclusion or alternative last exon)
during a specific biological process for example following inflammatory
activation. These tools are limited because of their dependence on a
fully annotated transcriptomes. Therefore if a lncRNA is unannotated or
has unannotated transcriptional isoforms, these events will not be
captured. To overcome the limitations of incomplete transcriptomes,
researchers can perform de novo transcriptome assembly using short
RNA-Seq reads [250–252].
The future of RNA sequencing is headed towards long read se-
quencing, which is being met by Pacific Biosciences Single Molecule
Real Time sequencing technology (PacBio) and Oxford Nanopore
Technology (ONT) [253,254]. While both powerful technologies per-
form long read sequencing, their platforms are very different. PacBio
technology is dependent on sequencing-by-synthesis. A DNA poly-
merase incorporates nucleotides that each have a corresponding con-
jugated fluorescent dye. The DNA polymerase works at a rate of
1000 bp/s, which is beyond the capabilities of current technologies.
However, by circularizing the DNA PacBio has overcome this limitation
through continuous long read sequencing, resulting in ability to gen-
erate 500k-4million reads at an error rate of below 1% [255,256]. On
the other hand, ONT's approach relies on a pore embedded in a mem-
brane. As a long cDNA or RNA strand translocates through the nano-
pore at single nucleotide precision from enzymatic regulation, the ionic
current across the membrane is recorded. This technology can sequence
full-length transcripts and can yield up to 10 million reads on the
MinION or up to 60 million reads on the PromethION for cDNA
[257,258]. An initial limitation of ONT was the 5–10% per read error
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rate, which has been overcome with a new technology called Rolling
Circle to Concatemeric Consensus (R2C2) bringing the error rate down
to 2.5% by increasing the read coverage. Overall, both of these tech-
nologies have overcome the transcriptome assembly and isoform
identification limitations of short-read Illumina sequencing [259].
As stated above, ONT and PacBio can perform long read cDNA se-
quencing [260] and even more exciting, both technologies can perform
direct long read RNA sequencing [261,262]. The beauty and simplicity
that ONT and PacBio offers is the ability to sequence the full expressed
isoform (cDNA and direct RNA), without worries of misidentifying a
complex splicing pattern, RNA cleavage events and also not relying on
transcript annotation files will lead to the identification of novel iso-
forms which are problems faced using short-read Illumina sequencing.
For lncRNAs there have been a couple of studies that focus on isoform
specificity and function for a given lncRNA. Neat1 [263] and lncRNA-
PXN-AS1 [264] are two studies that show how one gene can have dif-
ferent functions depending on the RNA isoform expressed. While these
studies are not immunology specific, this field is still at the early stages
and we anticipate it becoming more prevalent in future studies.
5.4. RNA modifications of lncRNAs
RNA modifications are widespread and diverse in chemical nature,
as well as highly conserved in their occurrence and function throughout
species. RNA modifications function to affect RNA stability, localiza-
tion, alternative site of poly-adenylation, and more [265]. Since
lncRNAs can function as decoys and scaffolds, which are highly de-
pendent on RNA structure, a single modification can enhance or era-
dicate this RNA-protein interaction. As you study a lncRNA, the me-
chanism of this molecule could be dependent on a modified nucleotide.
There are many techniques used to determine a single RNA mod-
ification in a cell type and biology of choice. Site-specific Cleavage and
Radioactive-labeling followed by ligation-assisted extraction and TLC
(SCARLET) Technology give scientists the ability to probe for N6-me-
thyladenosine RNA (m6A) modification status at single nucleotide re-
solution in mRNA and long noncoding RNA [266]. The significance of
RNA modifications to the control of the immune response is beginning
to be appreciated. A study by Winkler et al. showed that m6A mod-
ification controls the innate immune response to infection by targeting
type I interferons [267]. A few recent studies have shown that lncRNAs
do have RNA modifications such as MALAT1 containing m6A mod-
ifications [268,269], HOTAIR containing m5C and m6A [270,271] and
XIST containing ψ, m6A and m5C modifications [269]. A study by Zhou
et al. showed that the RNA modification, m6A, acts as a structural
‘switch’ in Malat1. When there is a modification at site 2515, it results
in an increased ability to bind hnRNPG, while a modification at 2577
leads to an increase in binding to hnRNPC [269]. In clinical research,
lncRNA RP11-139J23.1 is highly expressed in colorectal cancer cells
(CRC), and this specific upregulation was controlled by m6A methyla-
tion [272]. The study showed that m6A could regulate the lncRNA,
which in turn triggered the dissemination of CRC cells via post-trans-
lation upregulation of the protein Zeb1. This novel study, connecting
the interplay of RNA modifications and lncRNAs, has paved the way for
a novel predictive biomarker or therapeutic target in CRC [272].
There are over 160 identified RNA modifications, while only a few
have been studied to any extent [273]. Of these RNA modifications, the
way they are enriched for in analysis is through an assortment of
techniques including methylated RNA immunoprecipitation (MeRIP),
MeRIP-iCLIP (crosslinking and immunoprecipitation), Suicide enzyme
trap and Clickable chemicals (Reviewed in [274]). These techniques
have many limitations and biases, but hopefully, future studies using
direct RNA nanopore sequencing will overcome all these pitfalls. In a
recent study, direct RNA sequencing using nanopore technology
showed detection of m6A modifications with a 97% accuracy with the
design of synthetic sequences [275]. As the performance of the algo-
rithm increases, use of this tool will be extremely insightful when
Fig. 4. How to study lncRNAs?.
The flow-chart provides a “beginning to end” guide to study lncRNAs. Not all
suggested databases will be appropriate for all lncRNAs being studied. A.
Selection of candidate lncRNAs should factor in changes in expression, type of
lncRNA and nearby coding genes. B. Bioinformatic characterization of lncRNAs
can be done using a variety of online databases including: LNCipedia to assess
conservation or using the Mouse Cell Atlas (MCA) to assess tissue specific ex-
pression. C. Expression validation: This includes validation of expression and
confirming that the lncRNA is in-fact non-protein coding. D. Functional vali-
dation dives into the final stage of mechanistic characterization of a lncRNAs,
which involved manipulating its expression, as well as uncovering the specific
cis-elements within the transcript important for its function.
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analyzing myeloid or lymphoid primary cells with and without a
treatment to understand how RNA modifications are regulated in innate
immunity and specifically as it relates to our long noncoding tran-
scriptome.
6. Conclusions and future insights for the field
LncRNAs, including XIST and H19, have been studied intensely for
decades [275,276]. At the time we had no idea that these genes would
represent the largest family of RNA genes produced in the genome. As
Louis Pasteur once said, “Chance favors the prepared mind,” and this is
especially true following the development of next-generation sequen-
cing. RNA-sequencing provided an unprecedented insight into the
human genome. We did not identify new proteins, instead we found a
wealth of noncoding RNA transcripts. The lncRNA field is growing at a
blistering pace with labs from all aspects of biology, and now im-
munology branching out to include questions about the regulatory
impact of these pervasive long noncoding gene species. As detailed in
this review, there are many publicly available datasets and web servers
that will streamline how to begin a lncRNA project, from how to pick a
lncRNA candidate by interrogating published RNA-sequencing data, to
determine the best tools to use to study the function and mechanism of
a candidate (Fig. 4). Since this field is still at an early stage in its de-
velopment, there are some shortcomings, including poorly annotated
lncRNA transcripts. However, this will be overcome with direct RNA
sequencing using ONT and PacBio technology. These technologies will
enable us to determine the exact isoforms of transcripts expressed in a
particular cell and begin to catalog the different RNA modifications that
exist basally and during a biological process such as activation of in-
flammation. Since lncRNAs are cell-type specific in their expression
patterns continued development of single-cell sequencing technologies
will provide a complete catalog of lncRNAs in the genome. As the list of
annotated lncRNAs grows, characterizing the function of all these genes
has become a definite bottle-neck in the field. However, high-
throughput CRISPR screening provides an approach to quickly identify
functional lncRNAs in a particular biological system. Utilizing all the
tools outlined here should enable researchers to develop this field ra-
pidly. For our research focus, gaining a better understanding of the role
of lncRNAs in regulating immune responses will provide novel insights
into the molecular mechanisms governing inflammation. This data will
be critical for identifying new avenues for therapeutic intervention for
infectious and inflammatory disease.
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